The biosimilar name debate: what’s at stake for public health
Journal Title: Generics and Biosimilars Initiative Journal - Year 2014, Vol 3, Issue 1
Abstract
As the number of innovator biologics and biosimilars increases worldwide, a growing debate has focused on how these products should be named. The simple concept of a name can have significant impact on prescribing, dispensing, and adverse event reporting processes and, consequently, patient safety.
Authors and Affiliations
Emily A Alexander
Keywords
Related Articles
- EP ID EP354147
- DOI 10.5639/gabij.2014.0301.005
- Views 143
- Downloads 0
Rhythm
Clinical biosimilar data should be accessible to all Calls are growing for biosimilar manufacturers to publish their data in the public domain, particularly when developing versions of monoclonal antibodies that are asso...
Assessing biosimilarity using the method of generalized pivotal quantities
Introduction: For generic approval of small-molecule (chemical) drug products, US Food and Drug Administration requires evidence of equivalence in average bioavailability from bioavailability and bioequivalence studies....
Generic medicine pricing: on track in Europe?
There are many variables responsible for the pricing of generic medicines in Europe. This editorial looks at the many policy initiatives currently being undertaken.
Regional tenders on biosimilars in Italy: potentially competitive?
Introduction: Health care in Italy is mainly delivered through the country’s National Health Service (NHS), a public service funded by general taxation. The system is highly decentralized and each one of the 20 Regional...
Biosimilar monoclonal antibodies—challenges and opportunities in Europe
New regulations for the development of biosimilars have been introduced in Europe and a new class of biosimilars – monoclonal antibodies – is expected on the market soon, which will both challenge and benefit our healthc...